A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis

Authors
Category Primary study
JournalJOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY
Year 2004
This article has no abstract
Epistemonikos ID: 0e842807109aed2dbb3aa083e0d142ed8daf6368
First added on: Nov 13, 2025